1
|
Ahluwalia K, Du Z, Martinez-Camarillo JC, Naik A, Thomas BB, Pollalis D, Lee SY, Dave P, Zhou E, Li Z, Chester C, Humayun MS, Louie SG. Unveiling Drivers of Retinal Degeneration in RCS Rats: Functional, Morphological, and Molecular Insights. Int J Mol Sci 2024; 25:3749. [PMID: 38612560 PMCID: PMC11011632 DOI: 10.3390/ijms25073749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2024] [Revised: 03/12/2024] [Accepted: 03/22/2024] [Indexed: 04/14/2024] Open
Abstract
Retinal degenerative diseases, including age-related macular degeneration and retinitis pigmentosa, significantly contribute to adult blindness. The Royal College of Surgeons (RCS) rat is a well-established disease model for studying these dystrophies; however, molecular investigations remain limited. We conducted a comprehensive analysis of retinal degeneration in RCS rats, including an immunodeficient RCS (iRCS) sub-strain, using ocular coherence tomography, electroretinography, histology, and molecular dissection using transcriptomics and immunofluorescence. No significant differences in retinal degeneration progression were observed between the iRCS and immunocompetent RCS rats, suggesting a minimal role of adaptive immune responses in disease. Transcriptomic alterations were primarily in inflammatory signaling pathways, characterized by the strong upregulation of Tnfa, an inflammatory signaling molecule, and Nox1, a contributor to reactive oxygen species (ROS) generation. Additionally, a notable decrease in Alox15 expression was observed, pointing to a possible reduction in anti-inflammatory and pro-resolving lipid mediators. These findings were corroborated by immunostaining, which demonstrated increased photoreceptor lipid peroxidation (4HNE) and photoreceptor citrullination (CitH3) during retinal degeneration. Our work enhances the understanding of molecular changes associated with retinal degeneration in RCS rats and offers potential therapeutic targets within inflammatory and oxidative stress pathways for confirmatory research and development.
Collapse
Affiliation(s)
- Kabir Ahluwalia
- Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA; (K.A.); (A.N.); (P.D.); (E.Z.); (Z.L.); (C.C.)
| | - Zhaodong Du
- USC Ginsburg Institute of for Biomedical Therapeutics, University of Southern California, Los Angeles, CA 90033, USA; (Z.D.); (J.C.M.-C.); (B.B.T.); (D.P.); (S.Y.L.); (M.S.H.)
| | - Juan Carlos Martinez-Camarillo
- USC Ginsburg Institute of for Biomedical Therapeutics, University of Southern California, Los Angeles, CA 90033, USA; (Z.D.); (J.C.M.-C.); (B.B.T.); (D.P.); (S.Y.L.); (M.S.H.)
- Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
| | - Aditya Naik
- Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA; (K.A.); (A.N.); (P.D.); (E.Z.); (Z.L.); (C.C.)
| | - Biju B. Thomas
- USC Ginsburg Institute of for Biomedical Therapeutics, University of Southern California, Los Angeles, CA 90033, USA; (Z.D.); (J.C.M.-C.); (B.B.T.); (D.P.); (S.Y.L.); (M.S.H.)
- Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
| | - Dimitrios Pollalis
- USC Ginsburg Institute of for Biomedical Therapeutics, University of Southern California, Los Angeles, CA 90033, USA; (Z.D.); (J.C.M.-C.); (B.B.T.); (D.P.); (S.Y.L.); (M.S.H.)
- Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
| | - Sun Young Lee
- USC Ginsburg Institute of for Biomedical Therapeutics, University of Southern California, Los Angeles, CA 90033, USA; (Z.D.); (J.C.M.-C.); (B.B.T.); (D.P.); (S.Y.L.); (M.S.H.)
- Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
- Department of Physiology & Neuroscience, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA
| | - Priyal Dave
- Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA; (K.A.); (A.N.); (P.D.); (E.Z.); (Z.L.); (C.C.)
| | - Eugene Zhou
- Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA; (K.A.); (A.N.); (P.D.); (E.Z.); (Z.L.); (C.C.)
| | - Zeyang Li
- Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA; (K.A.); (A.N.); (P.D.); (E.Z.); (Z.L.); (C.C.)
| | - Catherine Chester
- Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA; (K.A.); (A.N.); (P.D.); (E.Z.); (Z.L.); (C.C.)
| | - Mark S. Humayun
- USC Ginsburg Institute of for Biomedical Therapeutics, University of Southern California, Los Angeles, CA 90033, USA; (Z.D.); (J.C.M.-C.); (B.B.T.); (D.P.); (S.Y.L.); (M.S.H.)
- Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
| | - Stan G. Louie
- Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA; (K.A.); (A.N.); (P.D.); (E.Z.); (Z.L.); (C.C.)
- USC Ginsburg Institute of for Biomedical Therapeutics, University of Southern California, Los Angeles, CA 90033, USA; (Z.D.); (J.C.M.-C.); (B.B.T.); (D.P.); (S.Y.L.); (M.S.H.)
| |
Collapse
|
2
|
Pollalis D, Calle AG, Martinez-Camarillo JC, Ahluwalia K, Hinman C, Mitra D, Lebkowski J, Lee SY, Thomas BB, Ahmed F, Chan V, Junge JA, Fraser S, Louie S, Humayun M. Scaling up polarized RPE cell supernatant production on parylene membrane. Exp Eye Res 2024; 240:109789. [PMID: 38242423 DOI: 10.1016/j.exer.2024.109789] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2023] [Revised: 01/09/2024] [Accepted: 01/10/2024] [Indexed: 01/21/2024]
Abstract
Age-related macular degeneration (AMD), a leading cause of vision loss, primarily arises from the degeneration of retinal pigment epithelium (RPE) and photoreceptors. Current therapeutic options for dry AMD are limited. Encouragingly, cultured RPE cells on parylene-based biomimetic Bruch's membrane demonstrate characteristics akin to the native RPE layer. In this study, we cultivated human embryonic stem cell-derived polarized RPE (hESC-PRPE) cells on parylene membranes at both small- and large-scale settings, collecting conditioned supernatant, denoted as PRPE-SF. We conducted a comprehensive analysis of the morphology of the cultured hESC-RPE cells and the secreted growth factors in PRPE-SF. To evaluate the in vivo efficacy of these products, the product was administered via intravitreal injections of PRPE-SF in immunodeficient Royal College of Surgeons (iRCS) rats, a model for retinal degeneration. Our study not only demonstrated the scalability of PRPE-SF production while maintaining RPE cell phenotype but also showed consistent protein concentrations between small- and large-scale batches. We consistently identified 10 key factors in PRPE-SF, including BMP-7, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-6, MANF, PEDF, PDGF-AA, TGFβ1, and VEGF. Following intravitreal administration of PRPE-SF, we observed a significant increase in the thickness of the outer nuclear layer (ONL) and photoreceptor preservation in iRCS rats. Furthermore, correlation analysis revealed that IGFBP-3, IGFBP-4, MANF, PEDF, and TGFβ1 displayed positive associations with in vivo bioactivity, while GDF-15 exhibited a negative correlation. Overall, this study highlights the feasibility of scaling up PRPE-SF production on parylene membranes without compromising its essential constituents. The outcomes of PRPE-SF administration in an animal model of retinal degeneration present substantial potential for photoreceptor preservation. Moreover, the identification of candidate surrogate potency markers, showing strong positive associations with in vivo bioactivity, lays a solid foundation for the development of a promising therapeutic intervention for retinal degenerative diseases.
Collapse
Affiliation(s)
- Dimitrios Pollalis
- USC Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; USC Ginsburg Institute for Biomedical Therapeutics, University of Southern California, Los Angeles, CA 90033, USA
| | - Alejandra Gonzalez Calle
- USC Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; USC Ginsburg Institute for Biomedical Therapeutics, University of Southern California, Los Angeles, CA 90033, USA
| | - Juan Carlos Martinez-Camarillo
- USC Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; USC Ginsburg Institute for Biomedical Therapeutics, University of Southern California, Los Angeles, CA 90033, USA
| | - Kabir Ahluwalia
- USC Ginsburg Institute for Biomedical Therapeutics, University of Southern California, Los Angeles, CA 90033, USA; USC Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA
| | - Cassidy Hinman
- USC Ginsburg Institute for Biomedical Therapeutics, University of Southern California, Los Angeles, CA 90033, USA
| | - Debbie Mitra
- USC Ginsburg Institute for Biomedical Therapeutics, University of Southern California, Los Angeles, CA 90033, USA
| | - Jane Lebkowski
- Regenerative Patch Technologies LLC, Menlo Park, CA 94028, USA
| | - Sun Young Lee
- USC Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; USC Ginsburg Institute for Biomedical Therapeutics, University of Southern California, Los Angeles, CA 90033, USA
| | - Biju B Thomas
- USC Ginsburg Institute for Biomedical Therapeutics, University of Southern California, Los Angeles, CA 90033, USA
| | - Faizah Ahmed
- USC Ginsburg Institute for Biomedical Therapeutics, University of Southern California, Los Angeles, CA 90033, USA
| | - Victoria Chan
- USC Ginsburg Institute for Biomedical Therapeutics, University of Southern California, Los Angeles, CA 90033, USA
| | - Jason A Junge
- Translational Imaging Center, University of Southern California, Los Angeles, CA 90089, USA
| | - Scott Fraser
- Translational Imaging Center, University of Southern California, Los Angeles, CA 90089, USA
| | - Stan Louie
- USC Ginsburg Institute for Biomedical Therapeutics, University of Southern California, Los Angeles, CA 90033, USA; USC Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA
| | - Mark Humayun
- USC Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; USC Ginsburg Institute for Biomedical Therapeutics, University of Southern California, Los Angeles, CA 90033, USA.
| |
Collapse
|
3
|
Mead AJ, Ahluwalia K, Ebright B, Zhang Z, Dave P, Li Z, Zhou E, Naik AA, Ngu R, Chester C, Lu A, Asante I, Pollalis D, Martinez JC, Humayun M, Louie S. Loss of 15-Lipoxygenase in Retinodegenerative RCS Rats. Int J Mol Sci 2024; 25:2309. [PMID: 38396985 PMCID: PMC10889776 DOI: 10.3390/ijms25042309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2024] [Revised: 02/08/2024] [Accepted: 02/12/2024] [Indexed: 02/25/2024] Open
Abstract
Retinitis pigmentosa (RP) is a retinal degenerative disease associated with a diversity of genetic mutations. In a natural progression study (NPS) evaluating the molecular changes in Royal College of Surgeons (RCS) rats using lipidomic profiling, RNA sequencing, and gene expression analyses, changes associated with retinal degeneration from p21 to p60 were evaluated, where reductions in retinal ALOX15 expression corresponded with disease progression. This important enzyme catalyzes the formation of specialized pro-resolving mediators (SPMs) such as lipoxins (LXs), resolvins (RvDs), and docosapentaenoic acid resolvins (DPA RvDs), where reduced ALOX15 corresponded with reduced SPMs. Retinal DPA RvD2 levels were found to correlate with retinal structural and functional decline. Retinal RNA sequencing comparing p21 with p60 showed an upregulation of microglial inflammatory pathways accompanied by impaired damage-associated molecular pattern (DAMP) clearance pathways. This analysis suggests that ALXR/FPR2 activation can ameliorate disease progression, which was supported by treatment with an LXA4 analog, NAP1051, which was able to promote the upregulation of ALOX12 and ALOX15. This study showed that retinal inflammation from activated microglia and dysregulation of lipid metabolism were central to the pathogenesis of retinal degeneration in RP, where ALXR/FPR2 activation was able to preserve retinal structure and function.
Collapse
Affiliation(s)
- Andrew James Mead
- Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA; (A.J.M.); (K.A.); (B.E.); (Z.Z.); (P.D.); (Z.L.); (E.Z.); (A.A.N.); (R.N.); (C.C.); (A.L.); (I.A.)
| | - Kabir Ahluwalia
- Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA; (A.J.M.); (K.A.); (B.E.); (Z.Z.); (P.D.); (Z.L.); (E.Z.); (A.A.N.); (R.N.); (C.C.); (A.L.); (I.A.)
| | - Brandon Ebright
- Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA; (A.J.M.); (K.A.); (B.E.); (Z.Z.); (P.D.); (Z.L.); (E.Z.); (A.A.N.); (R.N.); (C.C.); (A.L.); (I.A.)
| | - Zeyu Zhang
- Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA; (A.J.M.); (K.A.); (B.E.); (Z.Z.); (P.D.); (Z.L.); (E.Z.); (A.A.N.); (R.N.); (C.C.); (A.L.); (I.A.)
| | - Priyal Dave
- Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA; (A.J.M.); (K.A.); (B.E.); (Z.Z.); (P.D.); (Z.L.); (E.Z.); (A.A.N.); (R.N.); (C.C.); (A.L.); (I.A.)
| | - Zeyang Li
- Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA; (A.J.M.); (K.A.); (B.E.); (Z.Z.); (P.D.); (Z.L.); (E.Z.); (A.A.N.); (R.N.); (C.C.); (A.L.); (I.A.)
| | - Eugene Zhou
- Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA; (A.J.M.); (K.A.); (B.E.); (Z.Z.); (P.D.); (Z.L.); (E.Z.); (A.A.N.); (R.N.); (C.C.); (A.L.); (I.A.)
| | - Aditya Anil Naik
- Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA; (A.J.M.); (K.A.); (B.E.); (Z.Z.); (P.D.); (Z.L.); (E.Z.); (A.A.N.); (R.N.); (C.C.); (A.L.); (I.A.)
| | - Rachael Ngu
- Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA; (A.J.M.); (K.A.); (B.E.); (Z.Z.); (P.D.); (Z.L.); (E.Z.); (A.A.N.); (R.N.); (C.C.); (A.L.); (I.A.)
| | - Catherine Chester
- Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA; (A.J.M.); (K.A.); (B.E.); (Z.Z.); (P.D.); (Z.L.); (E.Z.); (A.A.N.); (R.N.); (C.C.); (A.L.); (I.A.)
| | - Angela Lu
- Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA; (A.J.M.); (K.A.); (B.E.); (Z.Z.); (P.D.); (Z.L.); (E.Z.); (A.A.N.); (R.N.); (C.C.); (A.L.); (I.A.)
| | - Isaac Asante
- Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA; (A.J.M.); (K.A.); (B.E.); (Z.Z.); (P.D.); (Z.L.); (E.Z.); (A.A.N.); (R.N.); (C.C.); (A.L.); (I.A.)
- University of Southern California Ginsburg Institute for Biomedical Therapeutics, University of Southern California, Los Angeles, CA 90033, USA; (D.P.); (J.C.M.); (M.H.)
- University of Southern California Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
| | - Dimitrios Pollalis
- University of Southern California Ginsburg Institute for Biomedical Therapeutics, University of Southern California, Los Angeles, CA 90033, USA; (D.P.); (J.C.M.); (M.H.)
- University of Southern California Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
| | - Juan Carlos Martinez
- University of Southern California Ginsburg Institute for Biomedical Therapeutics, University of Southern California, Los Angeles, CA 90033, USA; (D.P.); (J.C.M.); (M.H.)
- University of Southern California Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
| | - Mark Humayun
- University of Southern California Ginsburg Institute for Biomedical Therapeutics, University of Southern California, Los Angeles, CA 90033, USA; (D.P.); (J.C.M.); (M.H.)
- University of Southern California Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
| | - Stan Louie
- Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA; (A.J.M.); (K.A.); (B.E.); (Z.Z.); (P.D.); (Z.L.); (E.Z.); (A.A.N.); (R.N.); (C.C.); (A.L.); (I.A.)
- University of Southern California Ginsburg Institute for Biomedical Therapeutics, University of Southern California, Los Angeles, CA 90033, USA; (D.P.); (J.C.M.); (M.H.)
- University of Southern California Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
| |
Collapse
|
4
|
Ahluwalia K, Martinez-Camarillo JC, Thomas BB, Naik A, Gonzalez-Calle A, Pollalis D, Lebkowski J, Lee SY, Mitra D, Louie SG, Humayun MS. Polarized RPE Secretome Preserves Photoreceptors in Retinal Dystrophic RCS Rats. Cells 2023; 12:1689. [PMID: 37443724 PMCID: PMC10340490 DOI: 10.3390/cells12131689] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2023] [Revised: 06/19/2023] [Accepted: 06/20/2023] [Indexed: 07/15/2023] Open
Abstract
Retinal degenerative diseases, including age-related macular degeneration (AMD) and retinitis pigmentosa, lack effective therapies. Conventional monotherapeutic approaches fail to target the multiple affected pathways in retinal degeneration. However, the retinal pigment epithelium (RPE) secretes several neurotrophic factors addressing diverse cellular pathways, potentially preserving photoreceptors. This study explored human embryonic stem cell-derived, polarized RPE soluble factors (PRPE-SF) as a combination treatment for retinal degeneration. PRPE-SF promoted retinal progenitor cell survival, reduced oxidative stress in ARPE-19 cells, and demonstrated critical antioxidant and anti-inflammatory effects for preventing retinal degeneration in the Royal College of Surgeons (RCS) rat model. Importantly, PRPE-SF treatment preserved retinal structure and scotopic b-wave amplitudes, suggesting therapeutic potential for delaying retinal degeneration. PRPE-SF is uniquely produced using biomimetic membranes for RPE polarization and maturation, promoting a protective RPE secretome phenotype. Additionally, PRPE-SF is produced without animal serum to avoid immunogenicity in future clinical development. Lastly, PRPE-SF is a combination of neurotrophic factors, potentially ameliorating multiple dysfunctions in retinal degenerations. In conclusion, PRPE-SF offers a promising therapeutic candidate for retinal degenerative diseases, advancing the development of effective therapeutic strategies for these debilitating conditions.
Collapse
Affiliation(s)
- Kabir Ahluwalia
- Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA; (K.A.); (A.N.)
| | - Juan-Carlos Martinez-Camarillo
- USC Ginsburg Institute of for Biomedical Therapeutics, University of Southern California, Los Angeles, CA 90033, USA; (J.-C.M.-C.); (B.B.T.); (A.G.-C.); (D.P.); (S.Y.L.); (D.M.)
- USC Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
| | - Biju B. Thomas
- USC Ginsburg Institute of for Biomedical Therapeutics, University of Southern California, Los Angeles, CA 90033, USA; (J.-C.M.-C.); (B.B.T.); (A.G.-C.); (D.P.); (S.Y.L.); (D.M.)
- USC Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
| | - Aditya Naik
- Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA; (K.A.); (A.N.)
| | - Alejandra Gonzalez-Calle
- USC Ginsburg Institute of for Biomedical Therapeutics, University of Southern California, Los Angeles, CA 90033, USA; (J.-C.M.-C.); (B.B.T.); (A.G.-C.); (D.P.); (S.Y.L.); (D.M.)
- USC Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
| | - Dimitrios Pollalis
- USC Ginsburg Institute of for Biomedical Therapeutics, University of Southern California, Los Angeles, CA 90033, USA; (J.-C.M.-C.); (B.B.T.); (A.G.-C.); (D.P.); (S.Y.L.); (D.M.)
- USC Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
| | - Jane Lebkowski
- Regenerative Patch Technologies LLC, Menlo Park, CA 94028, USA;
| | - Sun Young Lee
- USC Ginsburg Institute of for Biomedical Therapeutics, University of Southern California, Los Angeles, CA 90033, USA; (J.-C.M.-C.); (B.B.T.); (A.G.-C.); (D.P.); (S.Y.L.); (D.M.)
- USC Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
- Department of Physiology & Neuroscience, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA
| | - Debbie Mitra
- USC Ginsburg Institute of for Biomedical Therapeutics, University of Southern California, Los Angeles, CA 90033, USA; (J.-C.M.-C.); (B.B.T.); (A.G.-C.); (D.P.); (S.Y.L.); (D.M.)
| | - Stan G. Louie
- Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA; (K.A.); (A.N.)
- USC Ginsburg Institute of for Biomedical Therapeutics, University of Southern California, Los Angeles, CA 90033, USA; (J.-C.M.-C.); (B.B.T.); (A.G.-C.); (D.P.); (S.Y.L.); (D.M.)
| | - Mark S. Humayun
- USC Ginsburg Institute of for Biomedical Therapeutics, University of Southern California, Los Angeles, CA 90033, USA; (J.-C.M.-C.); (B.B.T.); (A.G.-C.); (D.P.); (S.Y.L.); (D.M.)
- USC Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
| |
Collapse
|
5
|
Dong T, Dave P, Yoo E, Ebright B, Ahluwalia K, Zhou E, Asante I, Salimova M, Pei H, Lin T, Mead A, Li Z, Humayun M, Petasis NA, Epstein AL, Louie SG. NAP1051, a Lipoxin A4 Biomimetic Analogue, Demonstrates Antitumor Activity Against the Tumor Microenvironment. Mol Cancer Ther 2021; 20:2384-2397. [PMID: 34607931 DOI: 10.1158/1535-7163.mct-21-0414] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2021] [Revised: 07/26/2021] [Accepted: 09/27/2021] [Indexed: 11/16/2022]
Abstract
Resolving tumor-associated inflammation in the tumor microenvironment (TME) may promote antitumor effects. Lipoxin A4 (LXA4) is a short-lived endogenous bioactive lipid with potent anti-inflammatory and pro-resolving properties. Here, a biomimetic of LXA4, NAP1051, was shown to have LXA4-like in vitro properties and antitumor activity in colorectal cancer xenograft models. NAP1051 inhibited neutrophil chemotaxis toward fMLP and dose-dependently promoted dTHP-1 efferocytosis which was equipotent to aspirin-triggered lipoxin A4 (ATLA). In dTHP-1 cells, NAP1051 induced strong phosphorylation on ERK1/2 and AKT similar to formyl peptide receptor 2 (FPR2/ALX) agonists. In two mouse xenograft colorectal cancer models, NAP1051 significantly inhibited tumor growth when given orally at 4.8 to 5 mg/kg/day. Flow cytometric analyses showed that NAP1051 reduced splenic and intratumoral neutrophil and myeloid-derived suppressor cell populations, which correlated to the antitumor effect. In addition, NAP1051 reduced NETosis in the TME while stimulating T-cell recruitment. Overall, these results show that NAP1051 possesses key lipoxin-like properties and has antitumor activity against colorectal cancer via modulation of neutrophils and NETosis in the TME.
Collapse
Affiliation(s)
- Tiange Dong
- School of Pharmacy, University of Southern California, Los Angeles, California
| | - Priyal Dave
- School of Pharmacy, University of Southern California, Los Angeles, California
| | - EunJeong Yoo
- HD Biosciences, Wuxi Apptec, San Diego, California
| | - Brandon Ebright
- School of Pharmacy, University of Southern California, Los Angeles, California
| | - Kabir Ahluwalia
- School of Pharmacy, University of Southern California, Los Angeles, California
| | - Eugene Zhou
- School of Pharmacy, University of Southern California, Los Angeles, California
| | - Isaac Asante
- School of Pharmacy, University of Southern California, Los Angeles, California
| | - Malika Salimova
- School of Pharmacy, University of Southern California, Los Angeles, California
| | - Hua Pei
- School of Pharmacy, University of Southern California, Los Angeles, California
| | - Tracey Lin
- School of Pharmacy, University of Southern California, Los Angeles, California
| | - Andrew Mead
- School of Pharmacy, University of Southern California, Los Angeles, California
| | - Zeyang Li
- School of Pharmacy, University of Southern California, Los Angeles, California
| | - Mark Humayun
- Department of Ophthalmology, University of Southern California, Los Angeles, California
| | - Nicos A Petasis
- Department of Chemistry, University of Southern California, Los Angeles, California
| | - Alan L Epstein
- Department of Pathology, University of Southern California, Los Angeles, California
| | - Stan G Louie
- School of Pharmacy, University of Southern California, Los Angeles, California.
| |
Collapse
|
6
|
Ahluwalia K, Abernathy MJ, Beierle J, Cauchon NS, Cronin D, Gaiki S, Lennard A, Mady P, McGorry M, Sugrue-Richards K, Xue G. The Future of CMC Regulatory Submissions: Streamlining Activities Using Structured Content and Data Management. J Pharm Sci 2021; 111:1232-1244. [PMID: 34610323 DOI: 10.1016/j.xphs.2021.09.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2021] [Revised: 09/29/2021] [Accepted: 09/29/2021] [Indexed: 11/25/2022]
Abstract
Recent advancements in data engineering, data science, and secure cloud storage can transform the current state of global Chemistry, Manufacturing, and Controls (CMC) regulatory activities to automated online digital processes. Modernizing regulatory activities will facilitate simultaneous global submissions and concurrent collaborative reviews, significantly reducing global licensing timelines and variability in globally registered product details. This article describes advancements made within the pharmaceutical industry from theoretical concepts to utilization of structured content and data in CMC submissions. The term Structured Content and Data Management (SCDM) outlines the end-to-end scientific data lifecycle from capture in source systems, aggregation into a consolidated repository, and transformation into semantically structured blocks with metadata defining relationships between scientific data and business contexts. Automation of regulatory authoring (termed Structured Content Authoring) is feasible because SCDM makes data both human and machine readable. It will offer health authorities access to the digital data beyond the current standard of PDF documents and, for a review process, SCDM would "enrich the effectiveness, efficiency, and consistency of regulatory quality oversight" (Yu et al., 2019). SCDM is a novel solution for content and data management in regulatory submissions and can enable faster access to critical therapies worldwide.
Collapse
Affiliation(s)
- Kabir Ahluwalia
- Department of Global Regulatory Affairs - CMC, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA; University of Southern California, School of Pharmacy, 1985 Zonal Ave, Los Angeles, CA 90089, USA
| | - Michael J Abernathy
- Department of Global Regulatory Affairs - CMC, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA
| | - Jill Beierle
- Department of Global Regulatory Affairs - CMC, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA
| | - Nina S Cauchon
- Department of Global Regulatory Affairs - CMC, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA.
| | - David Cronin
- Cognition Corporation, 24 Hartwell Ave, Lexington, MA 02421, USA
| | - Sheetal Gaiki
- Biotherapeutic Development & Supply, Janssen Pharmaceuticals, 1000 Route 202 South, Raritan, NJ 08807, USA
| | - Andrew Lennard
- Department of Global Regulatory Affairs - CMC; Amgen Ltd, 1 Uxbridge Business Park, Sanderson Road, Uxbridge UB8 1DH, United Kingdom
| | - Pradeep Mady
- Product Quality Management, Janssen Pharmaceuticals, 1000 Route 202 South, Raritan, NJ 08807, USA
| | - Mike McGorry
- Biotherapeutic Development & Supply, Janssen Pharmaceuticals, Barnahely, Ringaskiddy, Co.Cork, Ireland
| | - Kathleen Sugrue-Richards
- Department of Global Regulatory Affairs - CMC, Amgen Inc., 40 Technology Way West Greenwich, RI 02817, USA
| | - Gang Xue
- Biotherapeutic Development & Supply, Janssen Pharmaceuticals, 200 Great Valley Pkwy, Malvern, PA 10355, USA
| |
Collapse
|
7
|
Dong T, Dave P, Ebright B, Ahluwalia K, Zhou E, Asante I, Salimova M, Pei H, Lin T, Mead A, Li Z, Petasis N, Louie S. Abstract 1436: Mechanistic investigation of NAP1051, a lipoxin A4 biomimetic, in treating colorectal cancer. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-1436] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: Resolving tumor-associated inflammation in the tumor microenvironment (TME) can restore the immune response against malignant tissue. Lipoxin A4 (LXA4) is a short-lived endogenous bioactive lipid with potent anti-inflammatory and pro-resolving properties. We developed a LXA4 biomimetic, NAP1051, with increased stability and longer half-life, and demonstrated its properties using in vitro assays and in vivo xenograft tumor models and explored the underlying mechanism of action (MoA).
Methods: Differentiated HL-60 and THP-1 induced by DMSO and PMA, respectively, were used as models. dHL-60 was used to determine the effect of NAP1051 on fMLP-induced neutrophil chemotaxis. NAP1051-induced dTHP-1 efferocytosis of apoptotic dHL-60 was measured using fluorescent microscopy. Concentration escalation and time of NAP1051 exposure were used to probe the molecular mechanism using Western Blot and RT-PCR. The efficacy of oral NAP1051 was evaluated in CT26 (CRC) xenograft model established in immunocompetent Balb/c mice with a dosage escalation design.
Results: NAP1051 inhibited neutrophil chemotaxis towards fMLP by > 40% at 1, 10 and 100 nM (p < 0.05). NAP1051 dose-dependently promoted dTHP-1 efferocytosis (p < 0.05) and was equipotent to ATLA4. In dTHP-1 cells, NAP1051 induced strong phosphorylation on ERK1/2 and AKT from 10 nM to 1 µM. When compared to ATLA4 and W-peptide, NAP1051 caused strong phosphorylation at both S473 and T308 of AKT. The NAP1051-induced p-ERK1/2 and p-AKT were in parallel and in a dose-dependent and time-dependent way. MoA studies revealed that such p-ERK1/2 was mediated by MEK1/2. However, NAP1051 led to p-AKT at both S473 and T308 despite PI3K inhibition, indicating a PI3K-independent pathway was involved. In the mouse xenograft CRC model, we demonstrated that NAP1051 significantly inhibit tumor growth when given p.o. at 5 mg/kg/day. Flow cytometry on splenic cells showed that NAP1051 reduced splenic neutrophil and MDSC populations, which correlated to the tumor sizes. IHC analyses revealed that NAP1051 decreased the intratumoral Ly6G+ neutrophils most significantly at 5 mg/kg/day (p<0.1). In combination with low-dose 5-FU and CTX, NAP1051 significantly decreased splenic neutrophils and MDSCs compared to chemotherapies alone (p<0.05).
Conclusions: NAP1051 has LXA4-like activity including inhibiting fMLP-mediated neutrophil chemotaxis and promoting macrophage efferocytosis of apoptotic cells. The molecular MoA of NAP1051 involves ERK1/2 and AKT signaling pathways which are interrelated closely. A PI3K-independent pathway may be activated and resulted in AKT activation. NAP1051 inhibited tumor growth significantly at 5 mg/kg/day in a CRC model with significant changes in splenic and intratumoral immune cell populations. With these properties, NAP1051 may be an effective component in the treatment of CRCs by modulating the inflammatory immune cells in the TME.
Citation Format: Tiange Dong, Priyal Dave, Brandon Ebright, Kabir Ahluwalia, Eugene Zhou, Isaac Asante, Malika Salimova, Hua Pei, Tracey Lin, Andrew Mead, Zeyang Li, Nicos Petasis, Stan Louie. Mechanistic investigation of NAP1051, a lipoxin A4 biomimetic, in treating colorectal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1436.
Collapse
Affiliation(s)
- Tiange Dong
- University of Southern California, Los Angeles, CA
| | - Priyal Dave
- University of Southern California, Los Angeles, CA
| | | | | | - Eugene Zhou
- University of Southern California, Los Angeles, CA
| | - Isaac Asante
- University of Southern California, Los Angeles, CA
| | | | - Hua Pei
- University of Southern California, Los Angeles, CA
| | - Tracey Lin
- University of Southern California, Los Angeles, CA
| | - Andrew Mead
- University of Southern California, Los Angeles, CA
| | - Zeyang Li
- University of Southern California, Los Angeles, CA
| | | | - Stan Louie
- University of Southern California, Los Angeles, CA
| |
Collapse
|
8
|
Lin T, Yoo J, Dave P, Mead A, Ahluwalia K, Dong T, Zhou E, Pei H, Asante I, Petasis N, Louie S. Abstract 4172: Oral administration of novel compound targeting triple negative breast cancer (TNBC) through the inhibition of SERCA2. Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-4172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Cancer survival is dependent on the increase of protein synthesis for cell migration, proliferation and metastasis. Cancer adaptive mechanisms include upregulation of endoplasmic reticulum (ER) activities to accommodate increases in misfolded proteins. Sarcoendoplasmic reticulum calcium ATPase (SERCA) are important regulators of calcium found in the endoplasmic reticulum, where inhibition can lead to protein misfolding. Since breast cancer cells express higher level of SERCA2, its overexpression maybe a target for drug development.
Method: Using an in vitro screening method to guide our development, we have developed a pharmacophore and made structural changes to enhance anti-cancer activity while reducing of COX-2 inhibition. In this effort, we have identified C1, a coxib analogue with improved antitumor activities with minimal COX-2 inhibitory properties. We have further tested C1 in nu/nu athymic mice xenograft with human breast cancer cell line (MDA MB 231). Tumor volume and animal weights were measured three times a week for 28 days. At the end of the study, tumor volume was correlated with molecular markers using RT-PCR and IHC staining.
Results: Our screening identified C1 as a promising anti-cancer compound in vitro and affirmed in xenograft triple negative breast cancer (TNBC) animal model. C1 has EC50 of <20 µM which was more potent than Di-methyl Celecoxib (DMC) and Celecoxib (CBX) with EC50 of ~30 µM and ~40 µM, respectively. Molecular dissection using western blot showed that C1 inhibited SERCA2 in both a time- and exposure-dependent manner. SERCA2 inhibition correlated with blocking the maturation of Notch 1. In vivo studies using oral administration of C1 showed optimal antitumor activity between 25-50 mg/kg/day, which resulted in >85% tumor reduction when compared to vehicle after 28 days of treatment. The safety of C1 was assessed for 48 days at 100 mg/kg/day, where no detectable biochemical, hematologic or histological toxicities were detected. RT-PCR analysis of residual tumor correlated with cell death indicated through the activation of CHOP and DR5 marker. Finally, C1 treatment also decreased angiogenesis markers VEGF-α and IL-8, corresponding to reduction in microvessel formation.
Conclusion: C1 is a bioavailable coxib analogue with minimal COX-2 inhibition while possessing broad spectrum antitumor activity, including TNBC. Treatment with C1 leads to dosage dependent antitumor properties as a consequence of specific SERCA2 inhibition. In dosage escalation studies up to 100 mg/kg/day, no detectable biochemical and histological toxicities were detected. With these properties, C1 may be an effective component in the treatment of TNBCs, where effective therapy(ies) is much needed.
Citation Format: Tracey J. Lin1, Julie Yoo2, Priyal Dave, Andrew Mead, Kabir Ahluwalia, Tiange Dong, Eugene Zhou, Hua Pei, Isaac Asante, Nicos Petasis, Stan Louie
Citation Format: Tracey Lin, Julie Yoo, Priyal Dave, Andrew Mead, Kabir Ahluwalia, Tiange Dong, Eugene Zhou, Hua Pei, Isaac Asante, Nicos Petasis, Stan Louie. Oral administration of novel compound targeting triple negative breast cancer (TNBC) through the inhibition of SERCA2 [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 4172.
Collapse
Affiliation(s)
- Tracey Lin
- University of Southern California, Los Angeles, CA
| | - Julie Yoo
- University of Southern California, Los Angeles, CA
| | - Priyal Dave
- University of Southern California, Los Angeles, CA
| | - Andrew Mead
- University of Southern California, Los Angeles, CA
| | | | - Tiange Dong
- University of Southern California, Los Angeles, CA
| | - Eugene Zhou
- University of Southern California, Los Angeles, CA
| | - Hua Pei
- University of Southern California, Los Angeles, CA
| | - Isaac Asante
- University of Southern California, Los Angeles, CA
| | | | - Stan Louie
- University of Southern California, Los Angeles, CA
| |
Collapse
|
9
|
Raji I, Ahluwalia K, Oyelere AK. Design, synthesis and evaluation of antiproliferative activity of melanoma-targeted histone deacetylase inhibitors. Bioorg Med Chem Lett 2017; 27:744-749. [PMID: 28131715 DOI: 10.1016/j.bmcl.2017.01.044] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2016] [Accepted: 01/13/2017] [Indexed: 10/20/2022]
Abstract
The clinical validation of histone deacetylase inhibition as a cancer therapeutic modality has stimulated interest in the development of new generation of potent and tumor selective histone deacetylase inhibitors (HDACi). With the goal of selective delivery of the HDACi to melanoma cells, we incorporated the benzamide, a high affinity melanin-binding template, into the design of HDACi to generate a new series of compounds 10a-b and 11a-b which display high potency towards HDAC1 and HDAC6. However, these compounds have attenuated antiproliferative activities relative to the untargeted HDACi. An alternative strategy furnished compound 14, a prodrug bearing the benzamide template linked via a labile bond to a hydroxamate-based HDACi. This pro-drug compound showed promising antiproliferative activity and warrant further study.
Collapse
Affiliation(s)
- Idris Raji
- School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA 30332-0400, USA
| | - Kabir Ahluwalia
- School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA 30332-0400, USA
| | - Adegboyega K Oyelere
- School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA 30332-0400, USA; Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA 30332-0400, USA.
| |
Collapse
|
10
|
Brier MJ, Stricker CT, Chambless DL, Chen J, Ahluwalia K, Mao JJ. Abstract PD4-02: Health beliefs predict adherence to aromatase inhibitors. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-pd4-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Post-menopausal breast cancer survivors are often prescribed aromatase inhibitors (AIs) to decrease the chance of cancer recurrence. Despite their efficacy, many survivors do not fully adhere to their AI regimen. To improve adherence rates, it is important to understand which patient factors are associated with adherence. Current research has mostly focused on demographic, cancer, and symptom variables, most of which cannot be modified. One relevant factor that may be modifiable is health beliefs, which include perceived susceptibility of cancer recurrence, perceived benefits of treatment, and perceived barriers to treatment. Among breast cancer patients, each of these has been found to be associated with adherence behaviors, such as mammography and tamoxifen adherence. In this study, we explored whether health beliefs also play a role in adherence to AIs. Objective: The purpose of this longitudinal study was to determine whether patients with lower perceived susceptibility to cancer recurrence, higher perceived barriers to taking AIs, and lower perceived benefits of AIs were more likely to non-adhere to their AI regimen. Method: Four hundred and thirty-seven breast cancer survivors who were currently on an AI completed a survey that included the Health Beliefs and Medication Adherence in Breast Cancer (HBMABC) scales (a measure adapted from the Champion Health Belief Model Scales (CHBMS) for Mammography Screening), as well as questions about their demographics and symptoms. Exploratory and confirmatory factor analysis of the HBMABC yielded a 3-factor solution: perceived susceptibility, perceived benefits, and perceived barriers. Adherence data, including drug holidays (taking breaks from AI treatment) and premature discontinuation (stopping AI treatment early), were collected from physicians' notes in patients' medical charts dating from the day they completed the survey through the end-date of their prescribed AI treatment. Bivariate analyses were conducted to determine variables that were predictive of non-adherence. Variables found to be associated with non-adherence were entered into multiple logistic regression analyses. Results: Eighty-five patients (20.6%) exhibited some form of non-adherence (premature discontinuation, drug holiday, or both). Joint pain severity and the number of years a patient was on an AI at the time of the survey were both associated with non-adherence. After adjusting for these covariates, perceived barriers to AI treatment was significantly associated with non-adherence (OR 1.76, 95% CI: 1.03 – 3.00, p = 0.04). No relationship was found between perceived susceptibility or perceived benefits, and AI adherence. Conclusions: Breast cancer patients on AIs who perceive greater barriers to AI treatment are more likely to non-adhere to their AI regimen. This finding suggests that clinicians can intervene to help modify patients' negative beliefs and ultimately help improve patients' adherence levels.
Citation Format: Brier MJ, Stricker CT, Chambless DL, Chen J, Ahluwalia K, Mao JJ. Health beliefs predict adherence to aromatase inhibitors. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr PD4-02.
Collapse
Affiliation(s)
- MJ Brier
- University of Pennsylvania, Philadelphia, PA; University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - CT Stricker
- University of Pennsylvania, Philadelphia, PA; University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - DL Chambless
- University of Pennsylvania, Philadelphia, PA; University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - J Chen
- University of Pennsylvania, Philadelphia, PA; University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - K Ahluwalia
- University of Pennsylvania, Philadelphia, PA; University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - JJ Mao
- University of Pennsylvania, Philadelphia, PA; University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| |
Collapse
|
11
|
Abu-Serriah M, Ahluwalia K, Shah KA, Bojanic S, Saeed N. A novel approach to chondrosarcoma of the glenoid fossa of the temporomandibular joint: a case report. J Oral Maxillofac Surg 2012; 71:208-13. [PMID: 22749519 DOI: 10.1016/j.joms.2012.04.005] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2011] [Revised: 04/02/2012] [Accepted: 04/03/2012] [Indexed: 01/19/2023]
Affiliation(s)
- Muammar Abu-Serriah
- Department of Oral & Maxillofacial Surgery, John Radcliffe Hospital, Oxford, England.
| | | | | | | | | |
Collapse
|
12
|
Abu-Serriah M, Ahluwalia K, Smith F, Bond S, Shah K. The frequency of neck metastasis in pT1 tongue squamous cell carcinoma in Oxford John Radcliffe Hospital. Br J Oral Maxillofac Surg 2012. [DOI: 10.1016/j.bjoms.2012.04.087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
13
|
Sood RK, Gupta AK, Ahluwalia SK, Dhadwal D, Sharma RK, Sood K, Gupta K, Ahluwalia K, Sharma K. An epidemiological study of obesity in Shimla Town. Indian J Med Sci 1996; 50:362-4. [PMID: 9057371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
A cross sectional study of 888 randomly selected subjects in Shimla town was done to determine prevalence of obesity, its relation to age and physical activity. The prevalence of obesity was 21.5% using cut off levels of BMI 25. The prevalence of obesity rose significantly with age. Obesity was less in those having moderate physical activity as compared to those with low and high activity. Primary prevention is required to tackle this disease risk factor through health education focussing on promotion of moderate regular physical activity.
Collapse
Affiliation(s)
- R K Sood
- Dept of Community Medicine, IG Medical College, Shimla
| | | | | | | | | | | | | | | | | |
Collapse
|
14
|
|